|
1
|
Spryszyńska S, Smok-Pieniążek A, Ferlińska
M, Roszak J, Nocuń M and Stępnik M: The influence of ATM, ATR,
DNA-PK inhibitors on the cytotoxic and genotoxic effects of
dibenzo[def,p]chrysene on human hepatocellular cancer cell line
HepG2. Mutat Res Genet Toxicol Environ Mutagen. 791:12–24. 2015.
View Article : Google Scholar
|
|
2
|
Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y,
Zhang J, Yuan J, Wang M, Chen D, Sun Y, et al: ATM-mediated
stabilization of ZEB1 promotes DNA damage response and
radioresistance through CHK1. Nat Cell Biol. 16:864–875. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benada J and Macurek L: Targeting the
checkpoint to kill cancer cells. Biomolecules. 5:1912–1937. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reddy V, Wu M, Ciavattone N, McKenty N,
Menon M, Barrack ER, Reddy GP and Kim SH: ATM inhibition
potentiates death of androgen receptor-inactivated prostate cancer
cells with telomere dysfunction. J Biol Chem. 290:25522–25533.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seol HJ, Yoo HY, Jin J, Joo KM, Kong DS,
Yoon SJ, Yang H, Kang W, Lim DH, Park K, et al: Prognostic
implications of the DNA damage response pathway in glioblastoma.
Oncol Rep. 26:423–430. 2011.PubMed/NCBI
|
|
6
|
Neumann J, Yang Y, Köhler R, Giaisi M,
Witzens-Harig M, Liu D, Krammer PH, Lin W and Li-Weber M: Mangrove
dolabrane-type of diterpenes tagalsins suppresses tumor growth via
ROS-mediated apoptosis and ATM/ATR-Chk1/Chk2-regulated cell cycle
arrest. Int J Cancer. 137:2739–2748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwok M, Davies N, Agathanggelou A, Smith
E, Petermann E, Yates E, Brown J, Lau A and Stankovic T: Synthetic
lethality in chronic lymphocytic leukaemia with DNA damage response
defects by targeting the ATR pathway. Lancet. 385(Suppl 1):
S582015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andrs M, Korabecny J, Nepovimova E, Jun D,
Hodny Z, Moravcova S, Hanzlikova H and Kuca K: The development of
ataxia telangiectasia mutated kinase inhibitors. Mini Rev Med Chem.
14:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Penedos A, Johnson AL, Strong E, Goldman
AS, Carballo JA and Cha RS: Essential and checkpoint functions of
budding yeast ATM and ATR during meiotic prophase are facilitated
by differential phosphorylation of a meiotic adaptor protein, Hop1.
PLoS One. 10:e01342972015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang XP, Liu F and Wang W: Two-phase
dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA.
108:8990–8995. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palmitelli M, de Campos-Nebel M and
González-Cid M: Progression of chromosomal damage induced by
etoposide in G2 phase in a DNA-PKcs-deficient context. Chromosome
Res. 23:719–732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ming M and He YY: PTEN in DNA damage
repair. Cancer Lett. 319:125–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ming M, Feng L, Shea CR, Soltani K, Zhao
B, Han W, Smart RC, Trempus CS and He YY: PTEN positively regulates
UVB-induced DNA damage repair. Cancer Res. 71:5287–5295. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen WH, Balajee AS, Wang J, Wu H, Eng C,
Pandolfi PP and Yin Y: Essential role for nuclear PTEN in
maintaining chromosomal integrity. Cell. 128:157–170. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosser CJ, Tanaka M, Pisters LL, Tanaka N,
Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA and Meyn
RE: Adenoviral-mediated PTEN transgene expression sensitizes
Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene
Ther. 11:273–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pappas G, Zumstein LA, Munshi A, Hobbs M
and Meyn RE: Adenoviral-mediated PTEN expression radiosensitizes
non-small cell lung cancer cells by suppressing DNA repair
capacity. Cancer Gene Ther. 14:543–549. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta A, Yang Q, Pandita RK, Hunt CR,
Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, et al: Cell
cycle checkpoint defects contribute to genomic instability in PTEN
deficient cells independent of DNA DSB repair. Cell Cycle.
8:2198–2210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paez J and Sellers WR: PI3K/PTEN/AKT
pathway. A critical mediator of oncogenic signaling. Cancer Treat
Res. 115:145–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee C, Kim JS and Waldman T: PTEN gene
targeting reveals a radiation-induced size checkpoint in human
cancer cells. Cancer Res. 64:6906–6914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Puc J, Keniry M, Li HS, Pandita TK,
Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE,
et al: Lack of PTEN sequesters CHK1 and initiates genetic
instability. Cancer Cell. 7:193–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ali IU: Gatekeeper for endometrium: The
PTEN tumor suppressor gene. J Natl Cancer Inst. 92:861–863. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei F, Xie Y, Tao L and Tang D: Both ERK1
and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7
cells by facilitating ATM activation. Cell Signal. 22:1783–1789.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakanishi A, Kitagishi Y, Ogura Y and
Matsuda S: The tumor suppressor PTEN interacts with p53 in
hereditary cancer (Review). Int J Oncol. 44:1813–1819.
2014.PubMed/NCBI
|
|
24
|
Conde-Perez A, Gros G, Longvert C,
Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow
F, et al: A caveolin-dependent and PI3K/AKT-independent role of
PTEN in β-catenin transcriptional activity. Nat Commun. 6:80932015.
View Article : Google Scholar
|
|
25
|
Puzio-Kuter AM, Laddha SV, Castillo-Martin
M, Sun Y, Cordon-Cardo C, Chan CS and Levine AJ: Involvement of
tumor suppressors PTEN and p53 in the formation of multiple
subtypes of liposarcoma. Cell Death Differ. 22:1785–1791. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ushio Y, Tada K, Shiraishi S, Kamiryo T,
Shinojima N, Kochi M and Saya H: Correlation of molecular genetic
analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients
with anaplastic astrocytoma and glioblastoma. Front Biosci.
8:e281–e288. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou M, Gu L, Findley HW, Jiang R and
Woods WG: PTEN reverses MDM2-mediated chemotherapy resistance by
interacting with p53 in acute lymphoblastic leukemia cells. Cancer
Res. 63:6357–6362. 2003.PubMed/NCBI
|
|
28
|
Bradbury JM and Jackson SP: ATM and ATR.
Curr Biol. 13:R4682003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang J, Xu ZP, Huang Y, Hamrick HE,
Duerksen-Hughes PJ and Yu YN: ATM and ATR: Sensing DNA damage.
World J Gastroenterol. 10:155–160. 2004.PubMed/NCBI
|
|
30
|
Shiloh Y: ATM and ATR: Networking cellular
responses to DNA damage. Curr Opin Genet Dev. 11:71–77. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nam C, Doi K and Nakayama H: Etoposide
induces G2/M arrest and apoptosis in neural progenitor cells via
DNA damage and an ATM/p53-related pathway. Histol Histopathol.
25:485–493. 2010.PubMed/NCBI
|
|
32
|
Kim KY, Cho YJ, Jeon GA, Ryu PD and Myeong
JN: Membrane-bound alkaline phosphatase gene induces antitumor
effect by G2/M arrest in etoposide phosphate-treated cancer cells.
Mol Cell Biochem. 252:213–221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Redon C, Pilch D, Rogakou E, Sedelnikova
O, Newrock K and Bonner W: Histone H2A variants H2AX and H2AZ. Curr
Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sánchez-Flores M, Pásaro E, Bonassi S,
Laffon B and Valdiglesias V: γH2AX assay as DNA damage biomarker
for human population studies: Defining experimental conditions.
Toxicol Sci. 144:406–413. 2015. View Article : Google Scholar
|
|
35
|
Rao VA, Conti C, Guirouilh-Barbat J,
Nakamura A, Miao ZH, Davies SL, Saccá B, Hickson ID, Bensimon A and
Pommier Y: Endogenous gamma-H2AX-ATM-Chk2 checkpoint activation in
Bloom's syndrome helicase deficient cells is related to DNA
replication arrested forks. Mol Cancer Res. 5:713–724. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Savic V, Yin B, Maas NL, Bredemeyer AL,
Carpenter AC, Helmink BA, Yang-Iott KS, Sleckman BP and Bassing CH:
Formation of dynamic gamma-H2AX domains along broken DNA strands is
distinctly regulated by ATM and MDC1 and dependent upon H2AX
densities in chromatin. Mol Cell. 34:298–310. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Riballo E, Kühne M, Rief N, Doherty A,
Smith GC, Recio MJ, Reis C, Dahm K, Fricke A, Krempler A, et al: A
pathway of double-strand break rejoining dependent upon ATM,
Artemis, and proteins locating to gamma-H2AX foci. Mol Cell.
16:715–724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mah LJ, El-Osta A and Karagiannis TC:
gammaH2AX: A sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Agarwal C, Tyagi A and Agarwal R: Gallic
acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via
ATM-Chk2 activation, leading to cell cycle arrest, and induces
apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther.
5:3294–3302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ahn J and Prives C: Checkpoint kinase 2
(Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage
regardless of threonine 68 phosphorylation. J Biol Chem.
277:48418–48426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang H, Hu M, Zhao R, Li P and Li M:
Dihydromyricetin suppresses the proliferation of hepatocellular
carcinoma cells by inducing G2/M arrest through the
Chk1/Chk2/Cdc25C pathway. Oncol Rep. 30:2467–2475. 2013.PubMed/NCBI
|
|
42
|
Bahassi M, Myer DL, McKenney RJ, Hennigan
RF and Stambrook PJ: Priming phosphorylation of Chk2 by polo-like
kinase 3 (Plk3) mediates its full activation by ATM and a
downstream checkpoint in response to DNA damage. Mutat Res.
596:166–176. 2006. View Article : Google Scholar
|
|
43
|
Amir S, Ma AH, Shi XB, Xue L, Kung HJ and
Devere White RW: Oncomir miR-125b suppresses p14ARF to
modulate p53-dependent and p53-independent apoptosis in prostate
cancer. PLoS One. 8:e610642013. View Article : Google Scholar
|
|
44
|
Mavridis K, Gueugnon F, Petit-Courty A,
Courty Y, Barascu A, Guyetant S and Scorilas A: The oncomiR miR-197
is a novel prognostic indicator for non-small cell lung cancer
patients. Br J Cancer. 112:1527–1535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fletcher CE, Dart DA, Sita-Lumsden A,
Cheng H, Rennie PS and Bevan CL: Androgen-regulated processing of
the oncomir miR-27a, which targets Prohibitin in prostate cancer.
Hum Mol Genet. 21:3112–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vazquez F and Devreotes P: Regulation of
PTEN function as a PIP3 gatekeeper through membrane interaction.
Cell Cycle. 5:1523–1527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul
D, McMurray JS, Fang X, Yung WK, Siminovitch KA, et al: Src family
protein-tyrosine kinases alter the function of PTEN to regulate
phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem.
278:40057–40066. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shehata M, Schnabl S, Demirtas D, Hilgarth
M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M,
et al: Reconstitution of PTEN activity by CK2 inhibitors and
interference with the PI3-K/Akt cascade counteract the
antiapoptotic effect of human stromal cells in chronic lymphocytic
leukemia. Blood. 116:2513–2521. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Stocker H, Andjelkovic M, Oldham S,
Laffargue M, Wymann MP, Hemmings BA and Hafen E: Living with lethal
PIP3 levels: Viability of flies lacking PTEN restored by a PH
domain mutation in Akt/PKB. Science. 295:2088–2091. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yu J, Zhang SS, Saito K, Williams S,
Arimura Y, Ma Y, Ke Y, Baron V, Mercola D, Feng GS, et al: PTEN
regulation by Akt-EGR1-ARF-PTEN axis. EMBO J. 28:21–33. 2009.
View Article : Google Scholar :
|
|
51
|
Alyasiri NS, Mehdi SJ, Alam MS, Ali A,
Mandal AK, Gupta S, Singh I and Rizvi MM: PTEN-mediated AKT
activation contributes to the reduced apoptosis among Indian oral
squamous cell carcinoma patients. J Cancer Res Clin Oncol.
138:103–109. 2012. View Article : Google Scholar
|
|
52
|
Abbott RT, Tripp S, Perkins SL,
Elenitoba-Johnson KS and Lim MS: Analysis of the
PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a
cell line microarray. Mod Pathol. 16:607–612. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH
and Tang HM: Mutation analysis of tumor suppressor gene PTEN in
patients with gastric carcinomas and its impact on PI3K/AKT
pathway. Oncol Rep. 24:89–95. 2010.PubMed/NCBI
|
|
54
|
Hande KR: Etoposide: Four decades of
development of a topoisomerase II inhibitor. Eur J Cancer.
34:1514–1521. 1998. View Article : Google Scholar
|
|
55
|
Théard D, Coisy M, Ducommun B, Concannon P
and Darbon JM: Etoposide and adriamycin but not genistein can
activate the checkpoint kinase Chk2 independently of ATM/ATR.
Biochem Biophys Res Commun. 289:1199–1204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fu X, Wan S, Lyu YL, Liu LF and Qi H:
Etoposide induces ATM-dependent mitochondrial biogenesis through
AMPK activation. PLoS One. 3:e20092008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wei F, Ojo D, Lin X, Wong N, He L, Yan J,
Xu S, Major P and Tang D: BMI1 attenuates etoposide-induced G2/M
checkpoints via reducing ATM activation. Oncogene. 34:3063–3075.
2015. View Article : Google Scholar
|
